Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin α4β1) are 2
attractive molecular targets for developing peptide radiopharmaceuticals for melanoma …

Melanocortin-1 receptor (MC1-R) and melanin are two attractive melanoma-specific targets
for peptide-targeted radionuclide therapy for melanoma. Radiolabeled peptides targeting …

Melanoma is a type of skin cancer known for its high aggressiveness, early dissemination of
metastases, and poor prognosis once metastasized. Thus, early diagnosis of melanoma is a …

Melanoma is a deadly disease at late metastatic stage, and early diagnosis and accurate
staging remain the key aspects for managing melanoma. The melanocortin 1 receptor (MC1 …

Scintigraphic imaging of metastatic melanoma lesions requires highly tumor‐specific
radiopharmaceuticals. Because both melanotic and amelanotic melanomas overexpress …

Melanocortin 1 receptor (MC1R) is specifically expressed in the majority of melanomas, a
leading cause of death related to skin cancers. Accurate staging and early detection is …

It is estimated that melanoma accounted for 76,380 new cases and 10,130 deaths in the
United States in 2016. The melanocortin 1 receptor (MC1R) is highly expressed in the vast …

INTRODUCTION: A novel alpha-melanocyte-stimulating hormone peptide analog CHX-A ″-
Re (Arg11) CCMSH, which targeted the melanocortin-1 receptor (MC1-R) overexpressed on …

Melanocortin type 1 receptor (MC1R), also known as α-melanocyte–stimulating hormone (α-
MSH) receptor, is an attractive molecular target for melanoma imaging and therapy. An 18F …

Peptide-targeted α-therapy with 7.4 MBq of 212Pb-[1, 4, 7, 10-tetraazacyclododecane-1, 4,
7, 10-tetraacetic acid]-ReO-[Cys3, 4, 10, d-Phe7, Arg11] α-MSH3–13 (212Pb-DOTA-Re …